Show simple item record

dc.contributor.authorDiaz, Asunción 
dc.contributor.authorDiez, Mercedes 
dc.contributor.authorBleda, Maria Jose 
dc.contributor.authorAldamiz, Mikel
dc.contributor.authorCamafort, Miguel
dc.contributor.authorCamino, Xabier
dc.contributor.authorCepeda, Concepcion
dc.contributor.authorCosta, Asuncion
dc.contributor.authorFerrero, Oscar
dc.contributor.authorGeijo, Paloma
dc.contributor.authorIribarren, Jose Antonio
dc.contributor.authorMoreno, Santiago
dc.contributor.authorMoreno, Maria Elena
dc.contributor.authorLabarga, Pablo
dc.contributor.authorPinilla, Javier
dc.contributor.authorPortu, Joseba
dc.contributor.authorPulido, Federico
dc.contributor.authorRosa, Carmen
dc.contributor.authorSantamaría, Juan Miguel
dc.contributor.authorTelenti, Mauricio
dc.contributor.authorTrapiella, Luis
dc.contributor.authorTrastoy, Monica
dc.contributor.authorViciana, Pompeyo
dc.date.accessioned2019-04-02T09:18:24Z
dc.date.available2019-04-02T09:18:24Z
dc.date.issued2010-09-14
dc.identifier.citationBMC Infect Dis. 2010 Sep 14;10:267.es_ES
dc.identifier.issn1471-2334es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7419
dc.description.abstractBACKGROUND: Previous studies have demonstrated the efficacy of treatment for latent tuberculosis infection (TLTBI) in persons infected with the human immunodeficiency virus, but few studies have investigated the operational aspects of implementing TLTBI in the co-infected population.The study objectives were to describe eligibility for TLTBI as well as treatment prescription, initiation and completion in an HIV-infected Spanish cohort and to investigate factors associated with treatment completion. METHODS: Subjects were prospectively identified between 2000 and 2003 at ten HIV hospital-based clinics in Spain. Data were obtained from clinical records. Associations were measured using the odds ratio (OR) and its 95% confidence interval (95% CI). RESULTS: A total of 1242 subjects were recruited and 846 (68.1%) were evaluated for TLTBI. Of these, 181 (21.4%) were eligible for TLTBI either because they were tuberculin skin test (TST) positive (121) or because their TST was negative/unknown but they were known contacts of a TB case or had impaired immunity (60). Of the patients eligible for TLTBI, 122 (67.4%) initiated TLTBI: 99 (81.1%) were treated with isoniazid for 6, 9 or 12 months; and 23 (18.9%) with short-course regimens including rifampin plus isoniazid and/or pyrazinamide. In total, 70 patients (57.4%) completed treatment, 39 (32.0%) defaulted, 7 (5.7%) interrupted treatment due to adverse effects, 2 developed TB, 2 died, and 2 moved away. Treatment completion was associated with having acquired HIV infection through heterosexual sex as compared to intravenous drug use (OR:4.6; 95% CI:1.4-14.7) and with having taken rifampin and pyrazinamide for 2 months as compared to isoniazid for 9 months (OR:8.3; 95% CI:2.7-24.9). CONCLUSIONS: A minority of HIV-infected patients eligible for TLTBI actually starts and completes a course of treatment. Obstacles to successful implementation of this intervention need to be addressed.es_ES
dc.description.sponsorshipThis work was funded by a grant (3041/99) from the Foundation for AIDS Research and Prevention in Spain (Fundación para la Investigación y la Prevención del SIDA en España-FIPSE).es_ES
dc.language.isoenges_ES
dc.publisherBiomed Centrales_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdult es_ES
dc.subject.meshAntitubercular Agents es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHIV Infections es_ES
dc.subject.meshHumans es_ES
dc.subject.meshLatent Tuberculosis es_ES
dc.subject.meshMale es_ES
dc.subject.meshMedication Adherence es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshProspective Studies es_ES
dc.subject.meshSpain es_ES
dc.subject.meshTreatment Outcome es_ES
dc.titleEligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spaines_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID20840743es_ES
dc.format.volume10es_ES
dc.format.number1es_ES
dc.format.page267es_ES
dc.identifier.doi10.1186/1471-2334-10-267es_ES
dc.contributor.funderFundación para la Investigación y la Prevención del Sida en España (FIPSE)es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.1186/1471-2334-10-267es_ES
dc.identifier.journalBMC infectious diseaseses_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional